Autoimmune Diseases News

Autoimmune Diseases	Welcome, Profile Billing Logout

«1 2...127 128 129 130 131132133 134 135 136 137...156 157 »

||||||||||  Lemtrada (alemtuzumab) / Sanofi
Enrollment change, MRI, Metastases:  iCAMMS-IST: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (clinicaltrials.gov) -  Jan 15, 2013
P3, N=25, Active, not recruiting,  Sponsor: University of British Columbia
N=20 --> 25

|||||||||| Enrollment change: Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases (clinicaltrials.gov) - Jan 15, 2013
P=N/A, N=400, Recruiting, Sponsor: National Eye Institute (NEI)
N=20 --> 25 N=200 --> 400

||||||||||  sirolimus / Generic mfg.
Enrollment change:  Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor (clinicaltrials.gov) -  Jan 15, 2013
P1/2, N=8, Terminated,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=200 --> 400 N=13 --> 8

||||||||||  H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
New P4 trial:  Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (clinicaltrials.gov) -  Jan 15, 2013
P4, N=10, Completed,  Sponsor: Fiechtner, Justus J., M.D., P.C.

||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial:  RA Denosumab on Bone Microstructure Study (clinicaltrials.gov) -  Jan 15, 2013
P4, N=40, Not yet recruiting,  Sponsor: Chinese University of Hong Kong

||||||||||  Cosentyx (secukinumab) / Novartis
New P3 trial:  REASSURE2: Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (clinicaltrials.gov) -  Jan 15, 2013
P3, N=234, Recruiting,  Sponsor: Novartis Pharmaceuticals

||||||||||  mavrilimumab (KPL-301) / Kiniksa
Trial initiation date:  A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) -  Jan 15, 2013
P2, N=172, Recruiting,  Sponsor: MedImmune LLC
N=13 --> 8 Initiation date: Nov 2012 --> Mar 2013

|||||||||| Enrollment closed, Immunomodulating: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 15, 2013
P=N/A, N=18, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Initiation date: Nov 2012 --> Mar 2013 Recruiting --> Active, not recruiting

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion:  A Pilot Trial of Rituxan in Refractory Myasthenia Gravis (clinicaltrials.gov) -  Jan 14, 2013
P1/2, N=10, Completed,  Sponsor: University of Vermont
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial completion: Locomotor Training in Persons With Multiple Sclerosis (clinicaltrials.gov) - Jan 14, 2013
P1/2, N=38, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Tysabri (natalizumab) / Biogen, Royalty
Enrollment change:  TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) -  Jan 14, 2013
P4, N=158, Completed,  Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=600 --> 158

|||||||||| Metastases: Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=96, Recruiting, Sponsor: University of Zurich

|||||||||| Enrollment open: Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=75, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
N=600 --> 158 Not yet recruiting --> Recruiting

||||||||||  Tysabri (natalizumab) / Biogen, Royalty
Trial completion:  TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) -  Jan 14, 2013
P4, N=158, Completed,  Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment closed:  A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy (clinicaltrials.gov) -  Jan 13, 2013
P1/2, N=10, Active, not recruiting,  Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Trial completion: Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids (clinicaltrials.gov) - Jan 13, 2013
P4, N=4659, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Humira (adalimumab) / Eisai, AbbVie
Trial completion:  Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice (clinicaltrials.gov) -  Jan 13, 2013
P=N/A, N=5747, Completed,  Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: Blood Glucose Awareness Training for Parents (clinicaltrials.gov) - Jan 13, 2013
P=N/A, N=77, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed N=58 --> 77

||||||||||  Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial:  To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) -  Jan 13, 2013
P3, N=200, Recruiting,  Sponsor: Sanofi

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy:  A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER) (clinicaltrials.gov) -  Jan 13, 2013
P3, N=71, Completed,  Sponsor: Hoffmann-La Roche
N=58 --> 77 Active, not recruiting --> Completed

|||||||||| Trial completion: Blood Glucose Awareness Training for Parents (clinicaltrials.gov) - Jan 13, 2013
P=N/A, N=77, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Isentress (raltegravir) / Merck (MSD)
New P2 trial:  INSPIREt: Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (clinicaltrials.gov) -  Jan 10, 2013
P2, N=24, Recruiting,  Sponsor: Queen Mary University of London

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Trial completion:  Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis (clinicaltrials.gov) -  Jan 10, 2013
P4, N=306, Completed,  Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Betaseron (IFN-β-1b) / Bayer
HEOR:  BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) -  Jan 9, 2013
P=N/A, N=300, Recruiting,  Sponsor: Bayer

||||||||||  atacicept (VT-001) / Vera Therap
Trial completion, P2/3 data:  Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (clinicaltrials.gov) -  Jan 9, 2013
P2/3, N=1007, Completed,  Sponsor: EMD Serono
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P3 trial: Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients. (clinicaltrials.gov) - Jan 9, 2013
P3, N=90, Recruiting, Sponsor: Centre Hospitalier Universitaire Dijon

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Monotherapy:  ADACTA: A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) -  Jan 9, 2013
P4, N=326, Completed,  Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P4 trial:  SEWORRA: Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis (clinicaltrials.gov) -  Jan 8, 2013
P4, N=30, Recruiting,  Sponsor: University Hospital, Rouen

||||||||||  Ocrevus (ocrelizumab) / Roche, Biogen
New P3 trial, P3 data:  Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG) (clinicaltrials.gov) -  Jan 8, 2013
P3, N=200, Recruiting,  Sponsor: Peter Fuhr

||||||||||  Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial:  RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) -  Jan 8, 2013
P3, N=700, Recruiting,  Sponsor: Sanofi

||||||||||  Rituxan (rituximab) / Roche
New P3 trial:  RITULUP: Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy (clinicaltrials.gov) -  Jan 8, 2013
P3, N=36, Recruiting,  Sponsor: Fundaci

||||||||||  poseltinib (HM71224) / Hanmi
New P1 trial:  Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers (clinicaltrials.gov) -  Jan 8, 2013
P1, N=62, Not yet recruiting,  Sponsor: Hanmi Pharmaceutical Company Limited

||||||||||  pepinemab (VX15) / Vaccinex
New P1 trial:  Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS (clinicaltrials.gov) -  Jan 8, 2013
P1, N=50, Recruiting,  Sponsor: Vaccinex Inc.

||||||||||  Orencia (abatacept) / BMS
Trial completion, PK/PD data:  Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients (clinicaltrials.gov) -  Jan 7, 2013
P2/3, N=118, Completed,  Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap
New P1 trial:  Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) -  Jan 7, 2013
P1, N=24, Active, not recruiting,  Sponsor: UCB, Inc.

||||||||||  Benlysta (belimumab) / GSK
New P2 trial:  Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy (clinicaltrials.gov) -  Jan 6, 2013
P2, N=0, Withdrawn,  Sponsor: GlaxoSmithKline

||||||||||  lansoprazole / Generic mfg., cyclosporine / Generic mfg.
New P3 trial:  The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes (clinicaltrials.gov) -  Jan 6, 2013
P3, N=60, Not yet recruiting,  Sponsor: Perle Bioscience, LLC.

||||||||||  omeprazole / Generic mfg., cyclosporine / Generic mfg.
New P3 trial:  The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (clinicaltrials.gov) -  Jan 6, 2013
P3, N=60, Not yet recruiting,  Sponsor: Perle Bioscience, LLC.

||||||||||  Naxozole (esomeprazole/naproxen) / Hanmi
Trial completion:  Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male (clinicaltrials.gov) -  Jan 3, 2013
P=N/A, N=68, Completed,  Sponsor: Hanmi Pharmaceutical Company Limited
Active, not recruiting --> Completed Not yet recruiting --> Completed

||||||||||  Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
Trial completion:  ACTHiMeN: Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy (clinicaltrials.gov) -  Jan 3, 2013
P2, N=20, Completed,  Sponsor: Radboud University
Not yet recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 2, 2013
P=N/A, N=50, Completed, Sponsor: Universita di Verona
Active, not recruiting --> Completed N=30 --> 50

|||||||||| Trial completion: Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 2, 2013
P=N/A, N=50, Completed, Sponsor: Universita di Verona
N=30 --> 50 Recruiting --> Completed

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change:  An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids (clinicaltrials.gov) -  Jan 2, 2013
P=N/A, N=23, Completed,  Sponsor: Hoffmann-La Roche
Recruiting --> Completed N=120 --> 23

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion:  An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids (clinicaltrials.gov) -  Jan 2, 2013
P=N/A, N=23, Completed,  Sponsor: Hoffmann-La Roche
N=120 --> 23 Recruiting --> Completed

||||||||||  dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap
Trial completion:  Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) -  Jan 2, 2013
P1, N=44, Completed,  Sponsor: UCB, Inc.
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy, MRI:  A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs (clinicaltrials.gov) -  Jan 2, 2013
P3, N=58, Completed,  Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  glatiramer acetate / Generic mfg.
Trial termination:  An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) -  Jan 1, 2013
P3, N=178, Terminated,  Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Completed Active, not recruiting --> Terminated

||||||||||  glatiramer acetate / Generic mfg.
Enrollment change:  An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) -  Jan 1, 2013
P3, N=178, Terminated,  Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Terminated N=1400 --> 178

||||||||||  Humira (adalimumab) / Eisai, AbbVie
Enrollment change:  Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 (clinicaltrials.gov) -  Jan 1, 2013
P=N/A, N=125, Active, not recruiting,  Sponsor: AbbVie (prior sponsor, Abbott)
N=1400 --> 178 N=172 --> 125

||||||||||  Cinryze IV (C1 esterase inhibitor [human] IV) / Takeda
New P1 trial:  C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (clinicaltrials.gov) -  Jan 1, 2013
P1, N=10, Completed,  Sponsor: Michael Levy



	Diseases Companies Products Productz Mechanisms of Action Sites